John Nuss

Company: Ventyx Biosciences

Job title: Chief Scientific Officer

Seminars:

NLRP3-Mediated Inflammation: Novel Strategy for Neurodegenerative & Cardiometabolic Disease Intervention 11:30 am

Characterizing NLRP3-driven inflammatory pathways across neurodegenerative and cardiometabolic diseases Advancing development of VTX3232 as a CNS-penetrant oral NLRP3 inhibitor to address high unmet clinical needs Demonstrating IL-1B and IL-6 modulation as a mechanism to impact both central and peripheral inflammation in patient populationsRead more

day: Conference Day One AM